Regulatory aspects on nanomedicines

2015/08/08 by Vanessa Sainz, João Conniot, Ana I. Matos +8 · 406 citations
Economics, Econometrics and Finance · Engineering · Immunology and Microbiology · Materials Science · Medicine · #Biosimilars and Bioanalytical Methods #Business #Computer science #Engineering #Engineering ethics #Health care #Knowledge management #Medicine #Nanoparticles: synthesis and applications #Pharmaceutical Economics and Policy #Political science #Risk analysis (engineering) #SAFER #Translational research

paper · doi:10.1016/j.bbrc.2015.08.023

published in Biochemical and Biophysical Research Communications 468(3), 504-510 (Elsevier BV)

openalex publication_date 2015/08/08 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/03

Cited by

• Exploring boron nitride nanotubes as potential drug delivery vehicles using density functional theory and molecular dynamics – An overview
• Nanomaterials for cancer therapy: current progress and perspectives
• Nanotechnology revolutionizing osteosarcoma treatment: Advances in targeted kinase inhibitors
• Nanobiotechnology: traditional re-interpreting personalized medicine through targeted therapies and regenerative solutions
• Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement
• Nano based drug delivery systems: recent developments and future prospects
• Ultrasmall-in-Nano Approach: Enabling the Translation of Metal Nanomaterials to Clinics
• Potential applications and human biosafety of nanomaterials used in nanomedicine. [europepmc]
• Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. [europepmc]
• Nanomedicine: Principles, Properties, and Regulatory Issues. [europepmc]
• Nano based drug delivery systems: recent developments and future prospects. [europepmc]
• Nanoparticles in Daily Life: Applications, Toxicity and Regulations. [europepmc]
• Graphene and other 2D materials: a multidisciplinary analysis to uncover the hidden potential as cancer theranostics. [europepmc]
• Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs. [europepmc]
• Protein-Based Nanoparticles as Drug Delivery Systems. [europepmc]
• Nanoparticle-Based Therapeutic Approach for Diabetic Wound Healing. [europepmc]
• Immune-mediated approaches against COVID-19. [europepmc]
• Gold Nanoparticles as a Potent Radiosensitizer: A Transdisciplinary Approach from Physics to Patient. [europepmc]
• Engineered Nanoparticles for Cancer Vaccination and Immunotherapy. [europepmc]
• Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy. [europepmc]
• Nanomaterials for cancer therapy: current progress and perspectives. [europepmc]
• MicroRNA Therapeutics in Cancer: Current Advances and Challenges. [europepmc]
• Current hurdles to the translation of nanomedicines from bench to the clinic. [europepmc]
• Polymeric Lipid Hybrid Nanoparticles (PLNs) as Emerging Drug Delivery Platform-A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications. [europepmc]
• Biocompatibility and Cytotoxicity of Gold Nanoparticles: Recent Advances in Methodologies and Regulations. [europepmc]
• Serum Albumin Nanoparticles: Problems and Prospects. [europepmc]
• A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. [europepmc]
• Methods of Liposomes Preparation: Formation and Control Factors of Versatile Nanocarriers for Biomedical and Nanomedicine Application. [europepmc]
• Precision Nanotoxicology in Drug Development: Current Trends and Challenges in Safety and Toxicity Implications of Customized Multifunctional Nanocarriers for Drug-Delivery Applications. [europepmc]
• PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective. [europepmc]
• Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs. [europepmc]
• Nanotechnology in healthcare, and its safety and environmental risks. [europepmc]